Daniel Morgenstern, Head of Clinical Trials at The Hospital for Sick Children, shared a post on LinkedIn:
“Newly published patient and family information about our The Hospital for Sick Children Therapeutic MIBG program for neuroblastoma.
Fingers crossed that the New Year brings Canadian and US supply of 131I-mIBG back on line so we can again offer this therapy to the patients who need it.”
More posts featuring Daniel Morgenstern.